Jean-pierre Van Geertruyden

This Phase 3 study is testing the MVA-BN mpox vaccine in 344 infants and children aged 4 to 24 months in the Democratic Republic of the Congo, a region heavily affected by mpox. Researchers are comparing a standard dose to a half-dose to see if the lower dose is still effective a…

This Phase 3 trial is testing the safety and immune response of the MVA-BN mpox vaccine in 359 pregnant and postpartum women in the Democratic Republic of the Congo. Some women receive the vaccine during pregnancy, others right after giving birth, and a small group gets it as an …